Hirudin As Alternative Anticoagulant- A Historical Review

Fritz Markwardt

doi:10.1055/s-2002-35292

Subscribe to RSS

Please copy the URL and add it into your RSS Feed Reader.

https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000077.xml

Share / Bookmark

Facebook Linkedin Weibo

Download PDF

Semin Thromb Hemost 2002; 28(5): 405-414
DOI: 10.1055/s-2002-35292

Hirudin As Alternative Anticoagulant- A Historical Review

Fritz Markwardt

Professor of Pharmacology, International Institute of Thrombosis and Vascular Diseases, Frankfurt/M, Germany

Further Information

Publication History

Publication Date:
06 November 2002 (online)

Abstract
Full Text
References

Buy Article Permissions and Reprints

ABSTRACT

Advances in separation techniques and biotechnology have contributed to the development of anticoagulant agents from hematophagous animals. The most potent known natural thrombin inhibitor from blood-sucking leeches (Hirudo medicinalis), hirudin has served as a standard for designing the natural coagulation inhibitors as an anticoagulant drug. The search for the development of hirudin from leech extract to genetically engineered products as an alternative anticoagulant has been resumed. The pharmacological profiling of the isolated thrombin inhibitor has shown that native hirudin is an antithrombotic agent of high quality. However, its clinical use has remained limited, because the substance has not been available in adequate amounts. The progress in molecular biology has stimulated the interest in the structure and function of hirudin. This development resulted in the production of recombinant hirudins (r-hirudins) through gene technology. The biological properties of hirudin combined with the ready availability of recombinant forms make the specific thrombin inhibitor well-suited for use as an antithrombotic drug. Its use should lead to a decisive progress in the management of thromboembolic diseases of both arterial and venous origin. Clinical trials, especially in diseases in which thrombin plays a crucial role, are in progress.

KEYWORDS

Hirudin - leeches - thrombin inhibitor - antithrombotic drug - pharmacology - history

REFERENCES

1 Markwardt F. Coagulation inhibitors from blood sucking animals-a new line of developing antithrombotic drugs. Pharmazie . 1996; 49 313-316

PubMed Search in Google Scholar
2 Markwardt F. Antithrombotic agents from hematophagous animals. Clin Appl Thromb Hemost . 1996; 2 75-82

PubMed Search in Google Scholar
3 Haycraft J B. Über die Einwirkung eines Sekretes des officiellen Blutegels auf die Gerinnbarkeit des Bluts. Naunyn Schmiedebergs Arch Exp Pathol Pharmacol . 1894; 18 209-217

PubMed Search in Google Scholar
4 Franz F. Über den die Blutgerinnung aufhebenden Bestandteil des medizinischen Blutegels. Naunyn Schmiedebergs Arch Exp Pathol Pharmacol . 1903; 49 342-357

PubMed Search in Google Scholar
5 Jacoby Y. Über Hirudin. Dtsch Med Wochenschr . 1904; 30 786-787

PubMed Search in Google Scholar
6 Markwardt F. Untersuchungen über Hirudin. Naturwissenschaften . 1955; 42 537-538

PubMed Search in Google Scholar
7 Markwardt F. Die antagonistische Wirkung des Hirudins gegen Thrombin in vivo. Naturwissenschaften . 1956; 43 111-112

PubMed Search in Google Scholar
8 Markwardt F. Untersuchungen über den Mechanismus der blutgerinnungshemmenden Wirkung des Hirudins. Naunyn Schmiedebergs Arch Exp Pathol Pharmacol . 1956; 229 389-399

PubMed Search in Google Scholar
9 Markwardt F. Die Isolierung und chemische Charakterisierung des Hirudins. Hoppe Seylers Z Physiol Chem . 1957; 308 147-156

PubMed Search in Google Scholar
10 Jutiz M, Charbonnel-Berault A, Marinoli G. Purification de l'hirudine. Bull Soc Chim Biol . 1963; 45 55-67

PubMed Search in Google Scholar
11 Markwardt F, Schäfer G, Töpfer H, Walsmann P. Die Isolierung des Hirudins aus medizinischen Blutegeln. Pharmazie . 1967; 22 239-241

PubMed Search in Google Scholar
12 Markwardt F, Walsmann P. Reindarstellung und Analyse des Thrombin-Inhibitors Hirudin. Hoppe Seylers Z Physiol Chem . 1967; 348 1381-1386

PubMed Search in Google Scholar
13 Markwardt F. Hirudin as an inhibitor of thrombin. In: Colowick SP, Kaplan NO, eds. Methods in Enzymology Vol. XIX. Proteolytic Enzymes. New York: Academic Press 1970: 924-932

Search in Google Scholar
14 Bagdy D, Barabas E, Graf L. Large scale preparation of hirudin. Thromb Res . 1973; 2 229-232

Crossref PubMed Search in Google Scholar
15 Walsmann P, Markwardt F. On the isolation of the thrombin inhibitor hirudin. Thromb Res . 1985; 40 563-570

Crossref PubMed Search in Google Scholar
16 Walsmann P. Isolation and characterization of hirudin from Hirudo medicinalis Semin Thromb Hemost . 1991; 17 83-87

PubMed Search in Google Scholar
17 Petersen T E, Roberts H R, Sotrup-Jensen L, Magnusson S. Primary structure of hirudin, a thrombin-specific inhibitor. In: Peeters H, ed. Protides of the Biologic Fluids Oxford, UK: Pergamon Press 1976: 145-149

Search in Google Scholar
18 Dodt J, Müller H P, Seemüller U, Chang J Y. The complete amino acid sequence of hirudin, a thrombin specific inhibitor. FEBS Lett . 1984; 65 180-183

PubMed Search in Google Scholar
19 Dodt J, Macheleit W, Seemüller U, Machler R, Fritz H. Isolation and characterization of hirudin isoinhibitors and sequence analysis of hirudin PA. Biol Chem Hoppe Seyler . 1986; 367 803-811

PubMed Search in Google Scholar
20 Kono S, Fenton II W J, Villanueva G B. Analysis of the secondary structure of hirudin and the mechanism of its interaction with thrombin. Arch Biochem Biophys . 1988; 267 158-166

Crossref PubMed Search in Google Scholar
21 Rydel T J, Rachchandran K Q, Tulinsky A. The structure of a complex of recombinant hirudin and human alpha-thrombin. Science . 1990; 49 277-280

PubMed Search in Google Scholar
22 Markwardt F. Biochemistry and pharmacology of hirudin. In: Pirkle H, Markland FS Jr, eds. Hemostasis and Animal Venoms New York: Dekker 1988: 255-269

Search in Google Scholar
23 Markwardt F. Development of hirudin as an antithrombotic agent. Semin Thromb Hemost . 1989; 15 269-282

PubMed Search in Google Scholar
24 Markwardt F. Die quantitative Bestimmung des Prothrombins durch Titration mit Hirudin. Naunyn Schmiedebergs Arch Exp Pathol Pharmacol . 1958; 232 487-498

PubMed Search in Google Scholar
25 Schmutzler R, Markwardt F. Der Hirudintest, eine Mikromethode zur Kontrolle des Prothrombinspiegels bei der Antikoagulantientherapie. Klin Wochenschr . 1962; 40 796-798

Crossref PubMed Search in Google Scholar
26 Markwardt F, Stürzebecher J, Walsmann P. The hirudin standard. Thromb Res . 1990; 59 395-400

Crossref PubMed Search in Google Scholar
27 Markwardt F. Versuche zur pharmakologischen Charakterisierung des Hirudins. Naunyn Schmiedebergs Arch Exp Pathol Pharmacol . 1958; 234 516-529

PubMed Search in Google Scholar
28 Markwardt F, Walsmann P. Die Reaktion zwischen Hirudin und Thrombin. Hoppe Seylers Z Physiol Chem . 1958; 312 85-98

PubMed Search in Google Scholar
29 Markwardt F, Hauptmann J, Nowak G, Klessen C, Walsmann P. Pharmacological studies on the antithrombotic action of hirudin in experimental animals. Thromb Haemost . 1982; 47 226-229

PubMed Search in Google Scholar
30 Markwardt F, Nowak G, Stürzebecher J. Pharmacokinetics and anticoagulant effect of hirudin in man. Thromb Haemost . 1984; 52 160-163

PubMed Search in Google Scholar
31 Markwardt F. Pharmacology of hirudin: one hundred years after the first report of the anticoagulant agent. Biomed Biochim Acta . 1985; 44 1007-1013

PubMed Search in Google Scholar
32 Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemost . 1991; 66 141-152

PubMed Search in Google Scholar
33 Markwardt F, Nowak G, Stürzebecher U, Walsmann P. Studies on the pharmacokinetics of hirudin. Biomed Biochim Acta . 1987; 46 237-244

PubMed Search in Google Scholar
34 Richter M, Walsmann P, Markwardt F. Plasma level of dextran-r-hirudin. Pharmazie . 1989; 44 73-74

PubMed Search in Google Scholar
35 Markwardt F, Richter M, Walsmann P, Riesener G, Paintz M. Preparation of dextran-bound recombinant hirudin and its pharmacokinetic behavior. Biomed Biochim Acta . 1990; 49 1103-1108

PubMed Search in Google Scholar
36 Markwardt F. The comeback of hirudin as an antithrombotic agent. Semin Thromb Hemost . 1991; 17 79-82

PubMed Search in Google Scholar
37 Vogel G, Markwardt F. Preliminary clinical reports on the antithrombotic action of hirudin. Thromb Res . 1987; 7(Suppl) 42-43

PubMed Search in Google Scholar
38 Markwardt F. Past, present and future of hirudin. Haemostasis . 1991; 21(Suppl 1) 11-26

PubMed Search in Google Scholar
39 Harvey R P, Degryse E, Stefani L. Cloning and expression of cDNA coding for the anticoagulant hirudin from the blood sucking leech, Hirudo medicinalis. Proc Nat Acad Sci USA . 1986; 83 1084-1088

PubMed Search in Google Scholar
40 Bergmann C, Dodt J, Köhler S, Fink E, Gassen H G. Chemical synthesis and expression of a gene coding for hirudin, the thrombin-specific inhibitor from the leech Hirudo medicinalis. Biol Chem Hoppe Seyler . 1986; 367 731-740

Crossref PubMed Search in Google Scholar
41 Märki W E, Grossenbacher H, Grüttner M G. Recombinant hirudin: genetic engineering and structure analysis. Semin Thromb Hemost . 1991; 17 88-93

PubMed Search in Google Scholar
42 Johnson P H, Sze P, Winant R, Payne P W, Lazur J B. Biochemistry and genetic engineering of hirudin. Semin Thromb Hemost . 1989; 15 302-315

PubMed Search in Google Scholar
43 Markwardt F. Le genie genetique conduit au retour de l'hirudine comme anticoagulant. Sang Thrombos Vaisseaux . 1991; 3 519-522

PubMed Search in Google Scholar
44 Markwardt F, Fink E, Kaiser B. Pharmacological survey of recombinant hirudin. Pharmazie . 1988; 43 202-207

PubMed Search in Google Scholar
45 Markwardt F, Nowak G, Stürzebecher J. Clinico-pharmacological studies with recombinant hirudin. Thromb Res . 1988; 52 393-400

Crossref PubMed Search in Google Scholar
46 Markwardt F, Kaiser B, Nowak G. Studies on antithrombotic effects of recombinant hirudin. Thromb Res . 1989; 54 377-388

Crossref PubMed Search in Google Scholar
47 Markwardt F, Novak G, Stürzebecher J. Clinical pharmacology of recombinant hirudin. Haemostasis . 1991; 21(Suppl 1) 133-136

PubMed Search in Google Scholar
48 Markwardt F. Hirudin and derivatives as anticoagulant agents. Thromb Haemost . 1991; 66 141-152

PubMed Search in Google Scholar
49 Stürzebecher J. Methods for determination of hirudin. Semin Thromb Hemost . 1991; 17 99-102

PubMed Search in Google Scholar
50 Walenga J M, Hoppensteadt D, Koza M, Pifarre R, Fareed J. Comparative studies on various assays for the laboratory evaluation of r-hirudin. Semin Thromb Hemost . 1991; 17 103-112

PubMed Search in Google Scholar
51 Nowak G, Bucha E. Quantitative determination of hirudin in blood and body fluids. Semin Thromb Hemost . 1996; 22 197-202

Thieme Connect PubMed Search in Google Scholar
52 Henschen A, Markwardt F, Walsmann P. Identification by HPLC analysis of the unaltered forms of hirudin and desulfated hirudin after kidney passage (Abst). Thromb Res . 1987; 7(Suppl) 37

PubMed Search in Google Scholar
53 Nowak G. Pharmacokinetics of hirudin. Semin Thromb Hemost . 1991; 17 145-149

PubMed Search in Google Scholar
54 Nowak G, Bucha E, Gööck T, Thieler H, Markwardt F. Pharmacology of r-hirudin in renal impairment. Thromb Res . 1992; 66 707-715

Crossref PubMed Search in Google Scholar
55 Eschenfelder V. Pharmacologic considerations in the development of hirudin and its derivatives for cardiovascular indications. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient Philadelphia, PA: Hanley and Belfus 1997: 161-174

Search in Google Scholar
56 Kaiser B, Markwardt F. Antithrombotic and haemorrhagic effects of synthetic and naturally occurring thrombin inhibitors. Thromb Res . 1986; 43 613-620

Crossref PubMed Search in Google Scholar
57 Brüggener E, Walsmann P, Markwardt F. Neutralization of hirudin anticoagulant action by DIP-thrombin. Pharmazie . 1989; 44 648-649

PubMed Search in Google Scholar
58 Fareed J, Walenga J M, Hoppensteadt D, Iyver L, Pifarre R. Neutralization of recombinant hirudin. Some practical considerations. Semin Thromb Hemost . 1991; 17 137-144

PubMed Search in Google Scholar
59 Markwardt F, Kaiser B, Richter M. Haemostyptic effects of batroxobin with regard to hirudin treatment. Thromb Res . 1992; 68 475-482

Crossref PubMed Search in Google Scholar
60 Markwardt F. Development of direct thrombin inhibitors in comparison to glycosaminoglycans. Semin Thromb Hemost . 2001; 27 523-530

Thieme Connect PubMed Search in Google Scholar
61 Markwardt F. The development of hirudin as an anticoagulant agent. Current Cardiovascular Patents . 1991; 1 981-995

PubMed Search in Google Scholar
62 Markwardt F. Hirudin: the promising antithrombotic. Cardiovascular Drug Reviews . 1992; 10 211-232

PubMed Search in Google Scholar
63 Markwardt F. The development of hirudin as an antithrombotic drug. In: Pifarre R, ed. New Anticoagulants for the Cardiovascular Patient Philadelphia, PA: Hanley and Belfus 1997: 145-160

Search in Google Scholar
64 Hauptmann J, Markwardt F. Pharmacologic aspects of the development of selective synthetic thrombin inhibitors as anticoagulants. Semin Thromb Hemost . 1992; 18 200-217

PubMed Search in Google Scholar